Erratum

Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) DOI: 10.1001/jamaneurol.2018.1212)

V. L. Stauffer, David William Dodick, Q. Zhang, J. N. Carter, J. Ailani, R. R. Conley

Research output: Contribution to journalComment/debate

Abstract

In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial,"1 published online May 29, 2018, there was an error in Figure 1. In the bottom middle box, reflecting the number of patients who completed double-blind treatment in the galcanezumab 240-mg dose group, the percentage should read 82.5%. This article was corrected online.

Original languageEnglish (US)
Number of pages1
JournalJAMA Neurology
Volume75
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Neurology
Migraine Disorders
Randomized Controlled Trials
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Erratum : Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) DOI: 10.1001/jamaneurol.2018.1212). / Stauffer, V. L.; Dodick, David William; Zhang, Q.; Carter, J. N.; Ailani, J.; Conley, R. R.

In: JAMA Neurology, Vol. 75, No. 9, 01.09.2018.

Research output: Contribution to journalComment/debate

@article{b9e9bf2ae58b426dbcaf7a57e1ea5627,
title = "Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) DOI: 10.1001/jamaneurol.2018.1212)",
abstract = "In the Original Investigation titled {"}Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial,{"}1 published online May 29, 2018, there was an error in Figure 1. In the bottom middle box, reflecting the number of patients who completed double-blind treatment in the galcanezumab 240-mg dose group, the percentage should read 82.5{\%}. This article was corrected online.",
author = "Stauffer, {V. L.} and Dodick, {David William} and Q. Zhang and Carter, {J. N.} and J. Ailani and Conley, {R. R.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1001/jamaneurol.2018.2840",
language = "English (US)",
volume = "75",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Erratum

T2 - Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) DOI: 10.1001/jamaneurol.2018.1212)

AU - Stauffer, V. L.

AU - Dodick, David William

AU - Zhang, Q.

AU - Carter, J. N.

AU - Ailani, J.

AU - Conley, R. R.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial,"1 published online May 29, 2018, there was an error in Figure 1. In the bottom middle box, reflecting the number of patients who completed double-blind treatment in the galcanezumab 240-mg dose group, the percentage should read 82.5%. This article was corrected online.

AB - In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial,"1 published online May 29, 2018, there was an error in Figure 1. In the bottom middle box, reflecting the number of patients who completed double-blind treatment in the galcanezumab 240-mg dose group, the percentage should read 82.5%. This article was corrected online.

UR - http://www.scopus.com/inward/record.url?scp=85053025141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053025141&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2018.2840

DO - 10.1001/jamaneurol.2018.2840

M3 - Comment/debate

VL - 75

JO - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 9

ER -